Completed PHASE1 INTERVENTIONAL 1-arm NCT01087021

Effect of Cabazitaxel on the QTc Interval in Cancer Patients (QT-Cab)

QT-Cab: An Open-Label Study to Investigate the Effect of Cabazitaxel on the QTc Interval in Cancer Patients

Sponsor: Sanofi

Updated 7 times since 2017 Last updated: Dec 15, 2011 Started: Mar 31, 2010 Primary completion: Apr 30, 2011 Completion: Nov 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Neoplasms, Malignant, this trial is completed. The trial is conducted by Sanofi and has accumulated 7 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bethlehem, United States , Brussels, Belgium , Decatur, United States , Ghent, Belgium , Herlev, Denmark , Kansas City, United States , København Ø, Denmark , Lund, Sweden , Maastricht, Netherlands , Paducah, United States and 5 more locations